Skip to Content
Morningstar
Get 14 Days Free

Merck & Co Inc MRK

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Adjuvant Cancer Data and Co-Formulations of Next Generation Drugs Highlighted at ASCO

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

At the annual American Society of Clinical Oncology (ASCO) meeting, data was presented that should support continued strong cancer drug sales for several wide-moat drug firms, including Merck, AstraZeneca, Roche, and Bristol-Myers. While we are not making any changes to our fair value estimates based on the data, we hold a stronger conviction in our longer-term projections based on the clinical updates. We believe the data presented in the adjuvant cancer settings (early-stage cancer) along with co-formulations of next generation drugs (such as LAG-3 targeted drugs) with currently marketed drugs hold the most potential.

Read Full Analysis

Company Profile

Business Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.

Contact
2000 Galloping Hill Road
Kenilworth, NJ, 07033
T +1 908 740-4000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type High Yield
Employees 74,000

Related

Commentary
The Week Ahead: Tesla, General Electric, and Facebook to Report Earnings
A long list of companies across several sectors will report.
Carole Hodorowicz
Our Picks
33 Undervalued Stocks for the Third Quarter
Here are our analysts' top ideas in each sector for the coming quarter.
Susan Dziubinski
Quarter-End Insights
Drugmakers, Biotech Pressured by Policy Risk, but We Don't Expect Big Regulatory Changes
We also expect a return to more elective procedures.
Damien Conover
Our Picks
10 Undervalued Wide-Moat Stocks
These are the cheapest names in the Morningstar Wide Moat Focus Index--plus stocks the index has recently added and dropped.
Susan Dziubinski
Market Update
5 Value Stocks With Room to Run
These wide-moat stocks are currently undervalued.
Lauren Solberg
Market Update
Are Vaccinemakers Attractive Today?
Here are a few drugmakers we like that are undervalued.
Sachin Nagarajan
Stock Analyst Update
Berkshire Once Again a Net Seller of Equities in Q1
The firm raised an estimated $7.7 billion from its sales of shares.
Greggory Warren
Our Picks
10 Superior Dividend Stocks
These stocks are good choices whether you're looking for dividend growth, down-market defense, or inflation protection.
Susan Dziubinski
Stock Strategist Industry Reports
Moderna Dominates COVID-19 Vaccine Manufacturers, at Least for Now
The global COVID-19 vaccine market is currently dominated by mRNA firms, but competitors are gaining strength.
Karen Andersen
Stock Analyst Update
Merck Posts Soft Q1 Pressured by COVID-19 Headwinds
We continue to view the stock as undervalued.
Damien Conover
Fund Spy
Funds That Buy Like Buffett, 2021
These funds hold the same stocks that the Oracle of Omaha does.
David Kathman
Commentary
The Week Ahead: Tesla, Microsoft, Boeing, Altria Group, and AbbVie to Report Earnings
The week ahead is packed with earnings reports from companies across all sectors.
Carole Hodorowicz
Stock Strategist
Moderna's Innovation Still Building a Moat
The company's COVID-19 vaccine has shown the vast potential of its mRNA technology.
Karen Andersen
Our Picks
11 Undervalued Climate-Friendly Stocks
These companies are well-positioned for a world less dependent on fossil fuels.
Susan Dziubinski
Our Picks
10 Solid Dividend-Paying Stocks on Sale
We think the payouts on these names are sustainable.
Susan Dziubinski
US Videos
3 Overlooked Dividend Stocks That Top Managers Like
These wide-moat firms are currently undervalued.
Morningstar
Our Picks
10 Undervalued Wide-Moat Stocks
Here's a peek at the cheapest constituents of the Morningstar Wide Moat Focus Index--as well as names that have been added and cut.
Susan Dziubinski
Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks
A majority of the top 10 dividend-yielding names are undervalued.
Malik Ahmed Khan
Our Picks
3 Warren Buffett Stocks to Buy
These undervalued stocks are among the top holdings in Berkshire Hathaway today.
Susan Dziubinski
Our Picks
5 Undervalued Dividend-Growth Stocks
These heavily weighted names in the Morningstar US Dividend Growth Index are all at least 10% undervalued.
Susan Dziubinski

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.